FGFR overexpression
|
Urothelial Cancer
|
FGFR overexpression
|
Urothelial Cancer
|
BAY 1163877 Sensitive: C3 – Early Trials
|
BAY 1163877 Sensitive: C3 – Early Trials
|
FGFR overexpression
|
NSCLC
|
FGFR overexpression
|
NSCLC
|
BAY 1163877 Sensitive: C3 – Early Trials
|
BAY 1163877 Sensitive: C3 – Early Trials
|
FGFR overexpression
|
SCCHN
|
FGFR overexpression
|
SCCHN
|
BAY 1163877 Sensitive: C3 – Early Trials
|
BAY 1163877 Sensitive: C3 – Early Trials
|
FGFR overexpression
|
Lung Cancer
|
FGFR overexpression
|
Lung Cancer
|
ARQ 087 Sensitive: D – Preclinical
|
ARQ 087 Sensitive: D – Preclinical
|
FGFR overexpression
|
HCC
|
FGFR overexpression
|
HCC
|
WXSH0011 Sensitive: D – Preclinical
|
WXSH0011 Sensitive: D – Preclinical
|
FGFR overexpression
|
Urothelial Cancer
|
FGFR overexpression
|
Urothelial Cancer
|
ARQ 087 Sensitive: D – Preclinical
|
ARQ 087 Sensitive: D – Preclinical
|
FGFR overexpression
|
Gastric Cancer
|
FGFR overexpression
|
Gastric Cancer
|
WXSH0011 Sensitive: D – Preclinical
|
WXSH0011 Sensitive: D – Preclinical
|